Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

ase Oprozomib Tablets in Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

  • Dr. Irene M. Ghobrial, Dana-Farber Cancer Institute
  • Sunday, December 8, 6:30 pm - 8:30 pm CT, Hall G
  • Poster presentation: Myeloma: Therapy, excluding Transplantation: Poster II
  • Abstract # 3184

Select Investigator-Sponsored carfilzomib abstracts:

Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethasone In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network

  • Dr. Pieter Sonneveld, Erasmus Medical Center, Rotterdam, Netherlands
  • Monday, December 9, 5:15 pm CT, 393-394
  • Oral Presentation: Myeloma: Therapy, excluding Transplantation II
  • Abstract # 688

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma

  • Dr. Sara Bringhen, Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
  • Monday, December 9, 4:30 pm CT, 393-394
  • Oral presentation: Myeloma: Therapy, excluding Transplantation II
  • Abstract # 685

A simple score, based on geriatric assessment, improves prediction of survival, and risk of serious adverse events in elderly newly diagnosed multiple myeloma patients

  • Dr. Alessandra Larocca, Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
  • M
    '/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... , ... (AAA) are so deadly, they kill 13,000 Americans every year. Minimally invasively emergency repair of ... data. The latest research on AAA is being presented at the 22nd annual International ... ...
... nitride nanotubes (BNNTs) are the divas of the nanoworld. ... temperamental compared to their carbon-based cousins. On the ... over 1,100 degrees Celsius, says Yoke Khin Yap, an ... nanotubes would burn like charcoal in a barbecue at ...
... , FT. LAUDERDALE, Fla. , Jan. 15 ... Green Hedge Fund to provide further investment for the company,s growth ... new level" is how CEO Chris Hamilton views this ... As controlling and ultimately reducing Carbon Emissions feature so highly on ...
Cached Biology Technology:Minimally Invasive Repair of Ruptured Aortic Aneurysm Could Save More Lives than Surgery 2Minimally Invasive Repair of Ruptured Aortic Aneurysm Could Save More Lives than Surgery 3Minimally Invasive Repair of Ruptured Aortic Aneurysm Could Save More Lives than Surgery 4Minimally Invasive Repair of Ruptured Aortic Aneurysm Could Save More Lives than Surgery 5Harnessing the divas of the nanoworld 2InfoSpi to Create $500m Green Hedge Fund Focusing on the Carbon Credit Market 2
(Date:4/24/2014)... - Purdue and West Virginia University researchers are the ... providing a bird,s-eye view of eagle features that could ... study calls into question long-held assumptions about golden eagle ... sensitive to ultraviolet light as previously thought. The genome ... sense of smell than researchers realized. , Additionally, ...
(Date:4/24/2014)... been published in the Scientific Reports journal. , ... (a joint centre of CSIC and Pompeu Fabra University-UPF), explains: ... and we saw that it did not match with the ... sequence the complete genome and to make a functional interpretation ... to Louis XVI". , The functional genome analysis was ...
(Date:4/24/2014)... study representing the largest study of animal intelligence to-date finds ... self-control. , Published this week in the journal Proceedings ... part of a long history of research aimed at understanding ... do things like make and use tools, read social cues, ... Until now, most studies of animal intelligence have focused on ...
Breaking Biology News(10 mins):Genome yields insights into golden eagle vision, smell 2The blood preserved in the pumpkin did not belong to Louis XVI 2Animals with bigger brains, broader diets have better self control 2Animals with bigger brains, broader diets have better self control 3
... This press release is available in German . ... a UFZ German scientist found that the worldwide ... pollinators, bees mainly, was 153 billion in 2005 for ... amounted to 9.5% of the total value of the ...
... been referred to as an "essential toxin" due to ... between the nutritious requirement and toxic effects upon exposure. ... have lead to the characterization of selenium as a ... narrow threshold concentration in ecosystems through anthropogenic activities. Ironically, ...
... Journalists are invited to attend the 20th EORTCNCIAACR ... Geneva, Switzerland [Geneva Palexpo, Geneva] from Tuesday 21 ... is the deadline for booking accommodation via the ... this symposium, organised jointly by the European Organisation ...
Cached Biology News:Economic value of insect pollination worldwide estimated at 153 billion euros 2Economic value of insect pollination worldwide estimated at 153 billion euros 3Biological selenium removal: The solution to pollution? 2Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics 2